Bio-Techne Q1 2025 Adj. EPS $0.42 Beats $0.38 Estimate, Sales $289.458M Beat $280.260M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne reported its Q1 2025 financial results, with adjusted EPS of $0.42 beating the estimate of $0.38, and sales of $289.458 million surpassing the expected $280.260 million.
October 30, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne's Q1 2025 earnings report shows a positive performance with both EPS and sales exceeding expectations.
Bio-Techne's better-than-expected EPS and sales figures indicate strong financial performance, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100